公开(公告)号：US11123409B2

公开(公告)日：2021-09-21

申请号：US15661300

申请日：2017-07-27

Applicant: INSTITUTE FOR BASIC SCIENCE ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  SEOUL NATIONAL UNIVERSITY HOSPITAL

Inventor： Jin-Soo Kim ,  Jeong Hun Kim ,  Sung Wook Park ,  Kyoungmi Kim

IPC: A61K38/46 ,  C12N15/11 ,  A61K48/00 ,  C12N15/113 ,  C12N9/22 ,  C12N15/10

Abstract: Provided are a method of preventing and/or treating an eye disease, using a Cas9 protein and a guide RNA targeting VEGF-A, and a ribonucleoprotein including a Cas9 protein and a guide RNA targeting VEGF-A.

公开(公告)号：US20210254054A1

公开(公告)日：2021-08-19

申请号：US17236660

申请日：2021-04-21

Applicant: TOOLGEN INCORPORATED ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  SEOUL NATIONAL UNIVERSITY HOSPITAL

Inventor： Jeong Hun KIM ,  Sung Wook PARK ,  Seokjoong KIM ,  Dong Woo SONG

IPC: C12N15/11 ,  C12N9/22 ,  A61K48/00 ,  C12N15/113 ,  C07K14/47 ,  C07K14/52 ,  C07K14/515 ,  C12N15/86 ,  A61K9/00 ,  A61K38/46

Abstract: The present invention relates to an artificially manipulated neovascularization-associated factor for regulating neovascularization and a use thereof. More particularly, the present invention relates to a system for artificially regulating neovascularization, which includes an artificially manipulated neovascularization-associated factor for regulating neovascularization and/or a composition for artificially manipulating the neovascularization-associated factor. In a specific aspect, a neovascularization regulatory system including a neovascularization-associated factor such as artificially manipulated VEGFA, HIF1A, ANGPT2, EPAS1, or ANGPTL4 and/or an expression product thereof is provided.

公开(公告)号：US20210051926A1

公开(公告)日：2021-02-25

申请号：US16846321

申请日：2020-04-11

Applicant: SEOUL NATIONAL UNIVERSITY HOSPITAL ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Hee Seung KIM ,  Jeong Mook LIM ,  Ji Yeon AHN ,  Na Ra LEE ,  Eun Ji LEE ,  Soo Jin PARK

IPC: A01K67/027

Abstract: The present invention relates to a method for preparing a large animal model, with peritoneal carcinomatosis, which is an abdominal cavity metastasis of tumor commonly found in advanced or recurrent solid cancer, is induced using a large animal, and the method for preparing a large animal model with peritoneal carcinomatosis comprises injecting a cancer cell line into the abdominal cavity of a piglet in which the immune function is not completed.
The method for preparing a large animal model with peritoneal carcinomatosis, when a human-derived immortalized cell line is inoculated into a pig, can overcome xenograft rejection and induce peritoneal carcinomatosis, can use animals with sufficient supply and demand, and can expect the spread of peritoneal carcinomatosis through breeding.

公开(公告)号：US20200271647A1

公开(公告)日：2020-08-27

申请号：US16721073

申请日：2019-12-19

Applicant: SEOUL NATIONAL UNIVERSITY HOSPITAL ,  Helixmith Co., Ltd. ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Jung Pyo LEE ,  Yong Chul KIM ,  Seung Hee YANG ,  Jae Gyun JEONG

IPC: G01N33/566 ,  G01N33/68 ,  G01N33/70 ,  C07K16/42

Abstract: A kit for diagnosing a renal disease or predicting prognosis of the renal disease from urine includes a binding molecule specifically bound to cMet protein contained in the urine. When a level of cMet protein in urine is higher than a normal group, this condition is diagnosed as the renal disease or predicted to have poor prognosis thereof. A screening method of a substance for treatment of renal disease includes first-measuring a level of cMet protein in urine of an object, injecting a sample to be analyzed into the object, and second-measuring the level of cMet protein in urine of the object. When the level of cMet protein in the second-measuring is lower than the level of cMet protein in the first-measuring, the sample to be analyzed is the substance for treatment of renal disease.

公开(公告)号：US20200157499A1

公开(公告)日：2020-05-21

申请号：US16773566

申请日：2020-01-27

Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  SEOUL NATIONAL UNIVERSITY HOSPITAL

Inventor： Sung Sup PARK ,  Ji Yeon KIM

IPC: C12N5/079 ,  A61K35/30 ,  G01N33/50

Abstract: Provided are a method of preparing retinal ganglion cells by differentiation of stem into retinal ganglion cells, retinal ganglion cells differentiated by the method, a method of screening for a death inhibitor or a proliferation promoter of retinal ganglion cells using the retinal ganglion cells differentiated by the method, a kit of screening for the death inhibitor or the proliferation promoter of retinal ganglion cells including the retinal ganglion cells differentiated by the method, a pharmaceutical composition for treating glaucoma or optic neuropathy including the retinal ganglion cells, a method of treating glaucoma or optic neuropathy including the step of administering the retinal ganglion cells to a subject suspected of having glaucoma or optic neuropathy, and a method of preparing a mature retinal ganglion cell line.

公开(公告)号：US20180237771A1

公开(公告)日：2018-08-23

申请号：US15953141

申请日：2018-04-13

Applicant: TOOLGEN INCORPORATED ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  SEOUL NATIONAL UNIVERSITY HOSPITAL

Inventor： Jeong Hun KIM ,  Sung Wook PARK ,  Seokjoong KIM ,  Dong Woo SONG

IPC: C12N15/11 ,  C12N9/22 ,  C12N15/86 ,  A61K38/46 ,  A61K9/00

Abstract: The present invention relates to an artificially manipulated neovascularization-associated factor for regulating neovascularization and a use thereof. More particularly, the present invention relates to a system for artificially regulating neovascularization, which includes an artificially manipulated neovascularization-associated factor for regulating neovascularization and/or a composition for artificially manipulating the neovascularization-associated factor. In a specific aspect, a neovascularization regulatory system including a neovascularization-associated factor such as artificially manipulated VEGFA, HIF1A, ANGPT2, EPAS1, or ANGPTL4 and/or an expression product thereof is provided.

公开(公告)号：US20240197816A1

公开(公告)日：2024-06-20

申请号：US18533699

申请日：2023-12-08

Applicant: NovMetaPharma Co., Ltd. ,  Seoul National University R&DB Foundation ,  SEOUL NATIONAL UNIVERSITY HOSPITAL

Inventor： Seung Hee Yang ,  Hoeyune Jung ,  Jong Min Kim ,  Yon Su Kim ,  Heonjong Lee

IPC: A61K38/12 ,  A61K45/06 ,  A61P37/06

CPC classification number: A61K38/12 ,  A61K45/06 ,  A61P37/06

Abstract: A treatment of rejection of a transplant by a recipient of the transplant is disclosed. Methods for prolonging transplant survival in a recipient of the transplant, prolonging survival of the recipient, delaying and/or suppressing delayed graft function in the recipient, and/or reducing the amount of an immunosuppressant administered for transplantation. The methods include providing the transplant with a CHP or a pharmaceutically acceptable salt thereof is disclosed. Also provided is a method for the production of a pharmaceutical composition for the treatment of a transplant allowing modulating transplant survival in a recipient of the transplant.

公开(公告)号：US20220387450A1

公开(公告)日：2022-12-08

申请号：US17820387

申请日：2022-08-17

Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  Seoul National University Hospital

Inventor： Kyong Soo PARK ,  Seung-Ah LEE ,  Sung Soo CHUNG

IPC: A61K31/575 ,  A61P3/10 ,  A61K31/609 ,  A61K31/58 ,  A61K38/19 ,  A61K31/395 ,  A61K31/132 ,  A61K31/7008 ,  A61K31/455

Abstract: The present invention relates to a composition for preventing or treating diabetes mellitus using a 4-component mixture of putrescine, glucosamine, nicotinamide, and a STAT3 inhibitor. It has been confirmed that blood glucose is stably regulated when a compound of the 4-component mixture according to the present invention is injected into the caudal vein of a diabetes mellitus-induced mouse. The compound can be practically and usefully used as a therapeutic agent for diabetes mellitus patients and patients exposed to diabetes mellitus risk.

公开(公告)号：US20220202897A1

公开(公告)日：2022-06-30

申请号：US17599211

申请日：2020-03-30

Applicant: NOVMETAPHARMA CO., LTD. ,  SEOUL NATIONAL UNIVERSITY HOSPITAL ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Hoe Yune JUNG ,  Heon Jong LEE ,  Jong Su JEON ,  Do Hyun LEE ,  Yon Su KIM ,  Seung Hee YANG ,  Yong Chul KIM ,  Jong Joo MOON ,  Ji Eun KIM

IPC: A61K38/12 ,  A61P19/04 ,  A61P11/00 ,  A61P1/16

Abstract: A Cyclo (his-pro) (CHP) is useful for preventing, ameliorating, or treating fibrosis. A pharmaceutical composition containing CHP may be used for preventing or treating fibrosis. A health functional food composition containing CHP may be used for preventing or ameliorating fibrosis. An antifibrotic composition, a method of preventing, ameliorating, or treating fibrosis by using CHP, and/or a use of CHP in the manufacture of the pharmaceutical composition for preventing or treating fibrosis are disclosed.

公开(公告)号：US20220193179A1

公开(公告)日：2022-06-23

申请号：US17599118

申请日：2020-03-30

Applicant: NOVMETAPHARMA CO., LTD. ,  SEOUL NATIONAL UNIVERSITY HOSPITAL ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Hoe Yune JUNG ,  Do Hyun LEE ,  Heon Jong LEE ,  Yon Su KIM ,  Seung Hee YANG

IPC: A61K38/01 ,  A61P43/00 ,  A23L33/18

Abstract: A cyclo(His-Pro)(CHP) is useful for preventing, alleviating or treating peritoneal fibrosis. A pharmaceutical composition for preventing or treating peritoneal fibrosis, a dietary supplement composition for preventing or alleviating peritoneal fibrosis, and a peritoneal dialysis solution, which all contain CHP is disclosed. Also disclosed are a method for preventing or treating peritoneal fibrosis by using CHP, a peritoneal dialysis method using CHP, a use of CHP during the preparation of a pharmaceutical composition for preventing or treating peritoneal fibrosis, and/or a use of CHP in the preparation of a peritoneal dialysis solution.